Document is current
Any future updates will be listed below
-
Authors
Savelieff, Masha G. https://orcid.org/0000-0001-5575-2494
Elafros, Melissa A. https://orcid.org/0000-0002-4511-201X
Viswanathan, Vijay https://orcid.org/0000-0001-9116-3937
Jensen, Troels S.
Bennett, David L. https://orcid.org/0000-0002-7996-2696
Feldman, Eva L. https://orcid.org/0000-0002-9162-2694
- License Information
-
More Information
Article History
Accepted: 29 October 2024
First Online: 5 December 2024
Competing interests
: T.S.J. has acted as consultant for Alnylam, Vectura, and the International Diabetic Federation. D.L.B. has acted as a consultant in the last 2 years for AditumBio, Amgen, Biogen, Biointervene, Combigene, LatigoBio, GSK, Ionis, Lexicon therapeutics, Lilly, Neuvati, Novo Ventures, Orion, Replay, SC Health Managers, Third Rock Ventures, and Vida Ventures. He has received research funding from Eli Lilly and Astra Zeneca. The other authors declare no competing interests.
